Nonparenchymal fluid is the source of increased mean diffusivity in preclinical Alzheimer's disease-Reference-Cited by-同舟云学术

Nonparenchymal fluid is the source of increased mean diffusivity in preclinical Alzheimer's disease

Published:2019-04-22 Issue:1 Volume:11 Page:348-354
ISSN:2352-8729
Container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
language:en
Short-container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Author:

Sepehrband Farshid¹,Cabeen Ryan P.¹,Barisano Giuseppe¹²,Sheikh‐Bahaei Nasim³⁴,Choupan Jeiran¹⁵,Law Meng¹⁶,Toga Arthur W.¹,

Affiliation:

1. Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern CaliforniaLos AngelesCAUSA

2. Neuroscience Graduate ProgramUniversity of Southern CaliforniaLos AngelesCAUSA

3. Department of RadiologyKeck School of Medicine, University of Southern CaliforniaLos AngelesCAUSA

4. Department of NeurologyKeck School of Medicine, University of Southern CaliforniaLos AngelesCAUSA

5. Department of PsychologyUniversity of Southern CaliforniaLos AngelesCAUSA

6. Radiology and Nuclear MedicineAlfred HealthMelbourneAustralia

Funder

Alzheimer's Disease Research Center, Emory University

Alzheimer's Disease Neuroimaging Initiative

National Institutes of Health

U.S. Department of Defense

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

AbbVie

Alzheimer's Association

Alzheimer's Drug Discovery Foundation

BioClinica

Biogen

Bristol-Myers Squibb

Eli Lilly and Company

Roche

Genentech

GE Healthcare

H. Lundbeck A/S

Merck

Novartis Pharmaceuticals Corporation

Pfizer

Servier

Takeda Pharmaceutical Company

Canadian Institutes of Health Research

NIH

USC

ADRC

DOD

ADNI

Araclon Biotech

BioClinica, Inc.

Bristol-Myers Squibb Company

CereSpir, Inc.

Cogstate

Eisai Inc.

Elan Pharmaceuticals, Inc.

EuroImmun

F. Hoffmann-La Roche Ltd

Genentech, Inc.

Fujirebio

IXICO Ltd.

Janssen Alzheimer Immunotherapy Research & Development, LLC.

Johnson & Johnson Pharmaceutical Research & Development LLC.

Lumosity

Lundbeck

Merck & Co., Inc.

Meso Scale Diagnostics, LLC.

NeuroRx Research

Neurotrack Technologies

Pfizer Inc.

Piramal Imaging

Transition Therapeutics

Publisher

Wiley

Subject

Psychiatry and Mental health,Clinical Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.dadm.2019.03.002

Reference73 articles.

1. A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study

2. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders

3. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis

4. White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease

5. Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ISMRM Clinical Focus Meeting 2023: “Imaging the Fire in the Brain”;Journal of Magnetic Resonance Imaging;2024-08-28

2. Diffusion magnetic resonance imaging of cerebrospinal fluid dynamics: Current techniques and future advancements;NMR in Biomedicine;2024-05-07

3. A comprehensive analysis of APOE genotype effects on human brain structure in the UK Biobank;Translational Psychiatry;2024-03-12

4. Imaging of enlarged perivascular spaces in Alzheimer’s disease with MRI techniques;Radiology Science;2024

5. Effects of sleep on brain perivascular space in a cognitively healthy population;Sleep Medicine;2023-11